{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:12Z","timestamp":1785131952941,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04237-8","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:13:40Z","timestamp":1781003620000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TFH phenotype and response to tucidinostat in relapsed\/refractory PTCL: analysis of patients from a phase IIb trial"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Yokohama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsuo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Gillings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"4237_CR1","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood.2023020912","volume":"144","author":"L Shea","year":"2024","unstructured":"Shea L, Mehta-Shah N. Peripheral T-cell lymphoma: are all patients high risk? Blood. 2024;144:2604\u201312.","journal-title":"Blood"},{"key":"4237_CR2","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4:4640\u20137.","journal-title":"Blood Adv"},{"key":"4237_CR3","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137:2161\u201370.","journal-title":"Blood"},{"key":"4237_CR4","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1200\/JCO.23.01687","volume":"42","author":"V Camus","year":"2024","unstructured":"Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, et al. Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral t-cell lymphoma: final analysis of the Ro-CHOP trial. J Clin Oncol. 2024;42:1612\u20138.","journal-title":"J Clin Oncol"},{"key":"4237_CR5","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","volume":"11","author":"J Dupuis","year":"2024","unstructured":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024;11:e406\u201314.","journal-title":"Lancet Haematol"},{"key":"4237_CR6","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","volume":"25","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Cordoba R, et al. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2024;25:1602\u201313.","journal-title":"Lancet Oncol"},{"key":"4237_CR7","unstructured":"WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). Lyon: IARC; 2017."},{"key":"4237_CR8","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E. The 5th edition of the World Health Organization classification of haematolymphoid tumours. Lymphoid Neoplasms Leukemia. 2022;36:1720\u20131748."},{"key":"4237_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"4237_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jcp-2025-210074","volume":"78","author":"AD Attygalle","year":"2025","unstructured":"Attygalle AD, Karube K, Jeon YK, Cheuk W, Bhagat G, Chan JKC, et al. The fifth edition of the WHO classification of mature T cell, NK cell and stroma-derived neoplasms. J Clin Pathol. 2025;78:217\u201332.","journal-title":"J Clin Pathol"},{"key":"4237_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00428-022-03412-6","volume":"482","author":"AL Feldman","year":"2023","unstructured":"Feldman AL, Laurent C, Narbaitz M, Nakamura S, Chan WC, de Leval L, et al. Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas. Virchows Arch. 2023;482:265\u201379.","journal-title":"Virchows Arch"},{"key":"4237_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811\u201321.","journal-title":"Haematologica"},{"key":"4237_CR13","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.3324\/haematol.2023.283992","volume":"109","author":"S Rai","year":"2024","unstructured":"Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, et al. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results. Haematologica. 2024;109:3357\u201362.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"4237_CR14","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1182\/blood-2025-1864","volume":"146","author":"H Liu","year":"2025","unstructured":"Liu H, Liu W, Huang W, Wang Y, Qiu L, Zou D. Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-na\u00efve TFH-derived peripheral T-cell lymphoma. Blood. 2025;146(Supplement 1):1864.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4237_CR15","doi-asserted-by":"publisher","first-page":"7779","DOI":"10.1182\/blood-2024-206953","volume":"144","author":"Q Cai","year":"2024","unstructured":"Cai Q, Xia Y, Zeng D, Li X, Fang X, Nie M, et al. Preliminary Results from a Phase II study of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with T follicular helper phenotype (SWIFT study). Blood. 2024;144(Supplement 1):7779.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04237-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04237-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:36Z","timestamp":1785128676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04237-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4237"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04237-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.I. has received honoraria from AbbVie, BeOne Medicines, Gilead, Bristol Myers Squibb, AstraZeneca, Nihon Shinyaku, Ono Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Genmab, Otsuka, Eisai, SymBio, MSD, Eli Lilly, and Recordati; has received consulting fees from Chugai, AbbVie, BeOne Medicines, Bristol Myers Squibb, AstraZeneca, Nihon Shinyaku, Genmab, Ono Pharmaceutical, Tanabe Pharma, Kyowa Kirin, Otsuka, Zenyaku, Daiichi Sankyo, Eisai, and Takeda; has received grants or contracts from AstraZeneca, AbbVie, Incyte, SymBio, Bristol Myers Squibb, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Ono Pharmaceuticals, Daiichi Sankyo, Chugai, BeOne Medicines, Genmab, LOXO Oncology, Otsuka, Regeneron, Gilead, and MSD. A.F. has received honoraria from Chugai, Novartis, AbbVie, and Genmab. S.R. has received honoraria from Meiji Seika Pharma and HUYA Bioscience International, Japan. D.M. has received honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai, Roche, Kyowa Kirin, MSD, Zenyaku, Sanofi, SymBio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, and BeOne Medicines; has received grants or contracts from Ono, Janssen, Eisai, Chugai, Kyowa Kirin, MSD, Sanofi, SymBio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Pfizer, Astellas, BeOne Medicines, Eli Lilly, Daiichi Sankyo, and Meiji Seika Pharma; and has served on advisory boards for Janssen, AstraZeneca, Chugai, AbbVie, Genmab, Sanofi, BMS, and Pfizer. K.O. has received honoraria from AbbVie, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, Chugai, CSL Behring, Genmab, Janssen, Kyowa Kirin, Nippon Shinyaku, Novartis, Ohara, Pfizer, SymBio, and Tanabe Pharma. A.Y. has received honoraria from Chugai and Janssen. K.T. has received honoraria from Eisai, Takeda, Meiji Seika Pharma, Sekisui Medical, Daiichi Sankyo, and Nippon Shinyaku; has received grants or contracts from Kyowa Kirin, Meiji Seika Pharma, Bristol Myers Squibb, Bayer, and Daiichi Sankyo; and has served on advisory boards for Meiji Seika Pharma, Daiichi Sankyo, and JIMRO. T.U. has received honoraria from Novartis, Janssen, AbbVie, Nippon Shinyaku, Meiji Seika Pharma, Eisai, Chugai, Asahi Kasei Pharma, Kissei, Sanofi, Bristol Myers Squibb, Kyowa Kirin, Nippon Kayaku, and Takeda. J.K. has received honoraria from Janssen, Bristol Myers Squibb, Eisai, BeOne Medicines, AbbVie, Chugai, Ono Pharmaceutical, AstraZeneca, Pfizer, Nippon Shinyaku, and Gilead; has received consulting fees from Janssen, Bristol Myers Squibb, Sanofi, BeOne Medicines, and AbbVie; and has received grants or contracts from Meiji Seika Pharma, Chugai, Eisai, Taiho Pharmaceutical, AbbVie, BeOne Medicines, Ono Pharmaceutical, AstraZeneca, Nippon Shinyaku, and Gilead. J.A. has received honoraria from AbbVie, Novartis, Chugai, Bristol\u2013Myers Squibb and Gilead. T.S. has received honoraria from AbbVie, Chugai, Astellas, Nihon Servier, HTLV-1 Zenkoku Net, Nippon Shinyaku, and AstraZeneca and has received grants or contracts from Daiichi Sankyo, Daiwa Securities Foundation, and PharmaEssentia. H.K. has received honoraria from Johnson & Johnson. H.M. has received honoraria from Asahi-Kasei Pharma, BeOne Medicines, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Kyowa Kirin, Genmab, Eli Lilly, Meiji Seika Pharma, Miyarisan, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Rakuten Medical, Shionogi, Taiho, and Takeda; his institution has also received grants or contracts from Asahi-Kasei Pharma, Chugai, CSL Behring, Daiichi Sankyo, Sumitomo Pharma, Kyowa Kirin, Nihon Kayaku, Nihon Shinyaku, Novartis, Otsuka, Teijin Pharma, Taiho, and Tsumura. S.Y. has received honoraria from Meiji Seika Pharma. M.G. is the President, CEO, and Executive Chair of HUYABIO International LLC and holds stock or stock options in HUYABIO International 8, Inc. H.O. is an employee of HUYABIO. K.T. received royalties or licenses from Sysmex, AMOY, and Nichirei Bioscience; consulting fees from Nichirei Bioscience, Nippon Shinyaku, and Meiji Seika Pharma; and honoraria from Chugai, Kyowa Kirin, SymBio, AstraZeneca, Eisai, Meiji Seika Pharma, and Janssen. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}